Adavosertib plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Trial Identifier: D6010C00004
Sponsor: AstraZeneca
NCTID:: NCT02272790
Start Date: January 2015
Primary Completion Date: December 2018
Study Completion Date: March 2023
Condition: Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
Dutch Translation
French Translation
Korean Translation
Spanish Translation

Trial Locations

Country Location
CA, ON Toronto, ON, CA, M5G 2M9
NL Amsterdam, NL, 1066 CX
US, AZ Gilbert, AZ, US, 85234
US, AZ Tucson, AZ, US, 85724
US, CA La Jolla, CA, US, 92093
US, CA Los Angeles, CA, US, 90024
US, CA San Francisco, CA, US, 94158
US, FL Tampa, FL, US, 33612
US, FL West Palm Beach, FL, US, 33401
US, GA Augusta, GA, US, 30912
US, MA Boston, MA, US, 02215
US, MI Detroit, MI, US, 48201
US, NY New York, NY, US, 10019
US, NY New York, NY, US, 10065
US, OH Cleveland, OH, US, 44195
US, OK Oklahoma City, OK, US, 73104
US, PA Abington, PA, US, 19001
US, TN Nashville, TN, US, 37203
US, TX Dallas, TX, US, 75390
US, WI Milwaukee, WI, US, 53226